However, a recent meta-analysis of randomized controlled clinical trials seem to find that the short-term use (24 weeks) of dapagliflozin associated with insulin for T1DM was not associated with an increased risk of diabetic ketoacidosis, but as highlighted by Authors additional high-quality studies are needed to determine its long-term safety [41]. Here, INS is linked to diabetic ketoacidosis.